Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review.
Louis PogodaFuat ZiylanDiederik P J SmeeingFrederick G DikkersRico N P M RinkelPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2022)
Systemically and intralesionally administered bevacizumab are effective treatment options for severe RRP. A systemic administration might be the treatment of first choice. Further prospective research with long term follow-up is advocated to elucidate this important topic.